Channel 1 Industry Satellite Symposia

CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes (ID 25)

Date
Wed, 05.05.2021
Time
19:00 - 20:00
Room
Channel 1
Chairs
  • J. Cortes Castan (Barcelona, Spain)
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Medical need to improve on standard therapies for HR+/HER2- EBC (ID 334)

Lecture Time
19:00 - 19:05
Speakers
  • J. Cortes Castan (Barcelona, Spain)
Session Name
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Individualizing therapeutic decision-making for patients with HR+/HER2- EBC (ID 337)

Lecture Time
19:05 - 19:15
Speakers
  • J. Cortes Castan (Barcelona, Spain)
Session Name
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Adjuvant therapy for patients with HR+/HER2- EBC at high risk of recurrence (ID 338)

Lecture Time
19:15 - 19:30
Speakers
  • S. Johnston (London, United Kingdom)
Session Name
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Debating optimal neoadjuvant therapy (ID 336)

Lecture Time
19:30 - 19:40
Speakers
  • S. Tolaney (Boston, MA, United States of America)
Session Name
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Future considerations on the horizon for HR+/HER2- EBC (ID 368)

Lecture Time
19:40 - 19:45
Speakers
  • S. Tolaney (Boston, MA, United States of America)
Session Name
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Summary, final thoughts and live Q&A (ID 339)

Lecture Time
19:45 - 19:55
Speakers
  • A. Speakers (, Switzerland)
Session Name
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00